Advaxis, MedImmune team trial - immuno-oncology
Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, entered into a clinical trial collaboration with MedImmune, the global research and development arm of organic products from AstraZeneca. Phase I / II study of immunotherapy will evaluate the safety and efficacy of anti-PD-L1 immune checkpoint inhibitor MedImmune investigation MEDI4736, in combination with vaccine immunotherapy main cancer Advaxis, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus (HPV) -Associated cervical cancer and head and neck associated with HPV.
both MEDI4736 ADXS-HPV and cancer immunotherapies are a new class of treatments that use the body's own immune system to help fight against cancer. MEDI4736 is designed to counter tactical evading immune tumor by blocking a signal that prevents the detection of tumors, while HPV-ADXS strengthens the ability of immune cells to fight against the tumor. Preclinical data suggest that the combination of ADXS-HPV with a checkpoint inhibitor, such as MEDI4736, can enhance the antitumor response overall.
"Our collaboration with Advaxis is further evidence of MedImmune's commitment to explore new combination of approaches as we progress our immuno-oncology portfolio," said Dr. Bahija Jallal, Executive Vice President, MedImmune. "We think there could be a significant clinical benefit of the combination of MEDI4736 with the vaccine against the specific cancer antigen Advaxis."
under the terms of the agreement, MedImmune Advaxis and evaluate the combination as a treatment for cancer associated HPV and cervical squamous cell carcinoma of the head and neck. it is expected that part of the Phase I trial to establish a recommended dose regime with MEDI4736 ADXS-HPV, and the game Phase II will evaluate the safety and efficacy of the combination. the study will be financed and carried out by Advaxis. the results of the study will be used to determine if further clinical development of this combination is justified.
Under the terms of the agreement, MedImmune has a non-exclusive relationship to tumor types led to HPV. MedImmune has the first right of negotiation for future development combinations involving MEDI4736 and ADXS-HPV.
"We are delighted to be in partnership with MedImmune and evaluate our MEDI4736 in combination with immunotherapy," said Daniel J. O'Connor, CEO, Advaxis. "This is the first time a PD-L1 inhibitor checkpoint will be used with a new class of immunotherapies. As more companies vie for a competitive advantage in the future market PD-L1, the ability of our platform immunotherapy to attack multiple tumor targets is an attractive combination therapy. "
EmoticonEmoticon